The Role of TRIP6, ABCC3 and CPS1 Expression in Resistance of Ovarian Cancer to Taxanes
Authors:
- Karolina SeborovaKSKarolina Seborova
- Alzbeta Kloudova-SpalenkovaAKAlzbeta Kloudova-Spalenkova
- Kamila KouckaKKKamila Koucka
- Petr HolyPHPetr Holy
- Marie EhrlichovaMEMarie Ehrlichova
- Changwei WangCWChangwei Wang
- Iwao OjimaIOIwao Ojima
- Iveta VoleskaIVIveta Voleska
- Petr DanielPDPetr Daniel
- Kamila BalusikovaKBKamila Balusikova
- Michael JelinekMJMichael Jelinek
- Jan KovarJKJan Kovar
Open Access
- 22 December 2021
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (1) , 73
Abstract
The main problem precluding successful therapy with conventional taxanes is de novo or acquired resistance to taxanes. Therefore, novel experimental taxane derivatives (Stony Brook taxanes; SB-Ts) are synthesized and tested as potential drugs against resistant solid tumors. Recently, we reported alterations in ABCC3, CPS1, and TRIP6 gene expression in a breast cancer cell line resistant to paclitaxel. The present study aimed to investigate gene expression changes of these three candidate molecules in the highly resistant ovarian carcinoma cells in vitro and corresponding in vivo models treated with paclitaxel and new experimental Stony Brook taxanes of the third generation (SB-T-121605 and SB-T-121606). We also addressed their prognostic meaning in ovarian carcinoma patients treated with taxanes. We estimated and observed changes in mRNA and protein profiles of ABCC3, CPS1, and TRIP6 in resistant and sensitive ovarian cancer cells and after the treatment of resistant ovarian cancer models with paclitaxel and Stony Brook taxanes in vitro and in vivo. Combining Stony Brook taxanes with paclitaxel caused downregulation of CPS1 in the paclitaxel-resistant mouse xenograft tumor model in vivo. Moreover, CPS1 overexpression seems to play a role of a prognostic biomarker of epithelial ovarian carcinoma patients’ poor survival. ABCC3 was overexpressed in EOC tumors, but after the treatment with taxanes, its up-regulation disappeared. Based on our results, we can suggest ABCC3 and CPS1 for further investigations as potential therapeutic targets in human cancers.Keywords
Funding Information
- Grantová Agentura České Republiky (19-03063S)
- Agentura Pro Zdravotnický Výzkum České Republiky (NU20-09-00174)
- Univerzita Karlova v Praze (PROGRES Q28)
- Czech Ministry of Education, Youth and Sports (INTER-COST, LTC19020)
- National Institutes of Health (R01 CA103314)
This publication has 71 references indexed in Scilit:
- ABCC3 as a marker for multidrug resistance in non-small cell lung cancerScientific Reports, 2013
- Mitochondria and cell signallingJournal of Cell Science, 2012
- Therapeutic strategies in epithelial ovarian cancerJournal of Experimental & Clinical Cancer Research, 2012
- Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cellsInvestigational New Drugs, 2009
- Lysophosphatidic Acid 2 Receptor-mediated Supramolecular Complex Formation Regulates Its Antiapoptotic EffectJournal of Biological Chemistry, 2009
- The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR ExperimentsClinical Chemistry, 2009
- Recent Advances in the Chemistry and Biology of New Generation TaxoidsJournal of Natural Products, 2009
- The Lysophosphatidic Acid 2 Receptor Mediates Down-regulation of Siva-1 to Promote Cell SurvivalJournal of Biological Chemistry, 2007
- Relative expression software tool (REST(C)) for group-wise comparison and statistical analysis of relative expression results in real-time PCRNucleic Acids Research, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001